Daiichi Sankyo

FDA Approves Enhertu for HER2-Low Metastatic Breast Cancer

Enhertu Racks Up Another EU Approval in Second-Line HER2-Positive Metastatic Breast Cancer

Byondis, Medac File for European Approval of SYD985 for HER2-Positive Breast Cancer

EMA's CHMP Backs Approval for Enhertu, Lynparza for Two Breast Cancer Indications

Daiichi Sankyo's Application for Enhertu in HER2-Low Breast Cancer to Commence European Review

Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Datopotamab Deruxtecan for TNBC

Enhertu Benefit in HER2-Low Breast Cancer Wows at ASCO; Signals Shifting Therapy, Dx Paradigms

Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications

Jury in Enhertu Patent Infringement Case Orders Daiichi Sankyo to Pay $41.8M in Damages

AstraZeneca, Daiichi Sankyo to Begin Regulatory Talks to Expand Enhertu Into HER2-Low Breast Cancer

In Brief This Week: AstraZeneca, Daiichi Sankyo, Orgenesis, Amgen

AstraZeneca, Daiichi Sankyo File for FDA Enhertu Approval in Second-Line HER2-Postive Breast Cancer

EMA to Review Daiichi Sankyo, AstraZeneca's Enhertu For Second-Line HER2-Positive Breast Cancer

Daiichi Sankyo, AstraZeneca Begin Phase III Trial of Enhertu in HER2-Mutant NSCLC

AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS

In Brief This Week: Daiichi Sankyo, AstraZeneca, Mary Bird Perkins Cancer Center, Guardant Health

In Brief This Week: AstraZeneca, Daiichi Sankyo, Turning Point, Recursion, Cleveland Clinic

European Society for Medical Oncology Congress 2021: Precision Oncology Data Roundup